Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a San Diego-based clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of novel therapeutics in the areas of immunology, inflammation, and oncology. Founded by the former executive team of Receptos, Gossamer Bio leverages a rich asset in-licensing environment with a focus on addressing high unmet medical needs.
The company's core strategy revolves around utilizing a team with a proven track record in key therapeutic areas such as immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising products:
- Seralutinib: Aimed at treating pulmonary arterial hypertension (PAH) by addressing cellular overgrowth, fibrosis, and vascular remodeling.
- GB004: Focused on treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
- GB1275: Targeting various oncology indications with innovative treatment strategies.
- GB001: Designed for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio's approach combines cutting-edge science with a commitment to improving patient outcomes. The company continuously works on expanding its pipeline through strategic partnerships and collaborations, ensuring a robust portfolio of therapeutic candidates.
Recent achievements include advancements in clinical trials for Seralutinib and GB004, showcasing the company's potential to deliver impactful treatments. Gossamer Bio remains focused on executing its mission to bring differentiated therapeutic solutions to patients with significant unmet needs.
For investors and stakeholders, Gossamer Bio represents a dynamic and innovative player in the biopharmaceutical space, committed to scientific excellence and patient-centric solutions.
Gossamer Bio (GOSS) reported Q3 2024 financial results with $327.0 million in cash and equivalents as of September 30, 2024. The company posted revenue of $9.5 million from collaborator contracts, R&D expenses of $34.9 million, and a net loss of $30.8 million ($0.14 per share). The company expects current funds to sustain operations into H1 2027.
The company continues enrollment in the PROSERA Study, a Phase 3 trial for seralutinib in PAH patients, with topline results expected in Q4 2025. Additionally, Gossamer plans to initiate a Phase 3 trial for PH-ILD treatment in mid-2025.
Gossamer Bio, a clinical-stage biopharmaceutical company, announced the approval of non-qualified stock option awards for five new non-executive employees. The Compensation Committee of Gossamer's Board of Directors granted options to purchase up to 221,000 shares of the company's common stock under the 2023 Employment Inducement Incentive Award Plan. These awards, granted on October 4, 2024, are in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.07 per share, equal to the closing price of Gossamer's common stock on the grant date. They have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 monthly installments, subject to continued employment.
Gossamer Bio (Nasdaq: GOSS) announced data presentations for seralutinib at the European Respiratory Society (ERS) Congress 2024 in Vienna. The presentations include additional findings from the Phase 2 TORREY open-label extension study, highlighting sustained effects of seralutinib beyond 24 weeks in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The data demonstrates continued improvement in clinical outcome measures and sustained effects on circulating biomarkers relevant to PAH pathogenesis. Two oral presentations and one poster presentation will showcase seralutinib's potential in making a meaningful difference for patients with pulmonary hypertension.
Gossamer Bio (GOSS) reported strong Q2 2024 financial results, highlighting a cash position of $354.5 million as of June 30, 2024. The company's focus remains on developing seralutinib for PAH and PH-ILD treatment. Key developments include:
1. Ongoing enrollment in the PROSERA Study, a Phase 3 trial for PAH, with topline results expected in Q4 2025.
2. Plans to start a Phase 3 trial for PH-ILD in mid-2025.
3. A collaboration with Chiesi Group for seralutinib development and commercialization.
4. Q2 revenue of $95.9 million, including $88.8 million from license sales.
5. Net income of $49.2 million, or $0.22 per share, compared to a net loss in Q2 2023.
The company expects its current cash position to fund operations into the first half of 2027.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical firm, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board approved non-qualified stock options for a new non-executive employee, effective June 5, 2024. The grant includes options to purchase up to 170,000 shares at an exercise price of $0.57 per share, equivalent to the closing price on the Nasdaq Global Select Market on that date. These options have a ten-year term and will vest over four years: 25% after one year, with the remaining shares vesting in 36 monthly installments. These inducement awards aim to attract new talent under Gossamer's 2023 Employment Inducement Incentive Award Plan.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, will present updated data on seralutinib at the American Thoracic Society 2024 International Conference from May 17-22 in San Diego.
The presentations will include interim results from the Phase 1B and Phase 2 TORREY open-label extension study in pulmonary arterial hypertension (PAH) and additional data on circulating biomarkers, inflammation, and fibrosis. The main presentation will be on May 19 by Dr. Olivier Sitbon.
Gossamer Bio, Inc. (NASDAQ: GOSS) granted non-executive employees stock options under the 2023 Inducement Plan. The options allow the purchase of up to 323,000 shares at $0.755 per share, vesting over four years. This grant aims to incentivize and retain new employees in accordance with Nasdaq rules.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced its first quarter 2024 financial results and business update. The company reported $396 million in cash, pro forma for a $160 million reimbursement payment and debt repayment. They are collaborating with Chiesi for seralutinib development and co-commercialization. The PROSERA Phase 3 study for PAH is ongoing, with top-line results expected in Q4 2025. A registrational Phase 3 study for PH-ILD is set to begin in mid-2025. TORREY Phase 2 PAH results were published in Lancet Respiratory Medicine, with additional data to be presented at ATS in May.
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize Seralutinib for pulmonary hypertension. Gossamer will receive development reimbursement and milestones payments, leading the US commercialization activities. Chiesi obtains exclusive ex-US commercial rights with Gossamer receiving royalties on net sales. A Phase 3 trial of Seralutinib in PH-ILD is planned for mid-2025.
Gossamer Bio, Inc. announced the publication of the TORREY Phase 2 study results in the Lancet Respiratory Medicine, showcasing the positive impact of seralutinib in treating pulmonary arterial hypertension. The study demonstrated significant improvements in pulmonary vascular resistance and other key disease measures. This milestone sets the stage for the Phase 3 PROSERA Study, highlighting the potential of seralutinib to enhance the quality of life for PAH patients.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio, Inc.?
Where is Gossamer Bio, Inc. located?
What are the main areas of focus for Gossamer Bio's therapeutic products?
Who founded Gossamer Bio, Inc.?
What is Seralutinib used for?
What conditions does GB004 target?
What is GB1275 used to treat?
What stage is Gossamer Bio at in its development?
How does Gossamer Bio expand its pipeline?